Diabetes Trials Unit
The Diabetes Trials Unit (DTU) is a UKCRC accredited clinical trials unit specialising in performing local, national and multinational clinical trials related to treating and managing diabetes and other cardiometabolic and related conditions. We work collaboratively with researchers and organisations to support trials and other studies.
Director
-
Amanda Adler
Professor of Diabetic Medicine and Health Policy
What's new
Under-40s diagnosed with type 2 diabetes have a mortality rate four times higher than the general population
24 October 2024
People diagnosed with type 2 diabetes before 40 years of age, have nearly four times the risk of death compared with the general UK population, a new study carried out at the University of Oxford’s Radcliffe Department of Medicine has found.
Hydroxychloroquine provides moderate COVID-19 prevention
16 September 2024
COPCOV, the world’s largest COVID-19 chemoprevention study, published results today showing that hydroxychloroquine (HCQ) has a moderate benefit in preventing COVID-19. The COPCOV trial was led globally by the Mahidol Oxford Tropical Medicine Research Unit (MORU), Thailand. The Diabetes Trials Unit (DTU) was the UK coordinating centre for the trial, helped develop the protocol, and was responsible for managing UK sites, approvals and procedures.
Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found
10 September 2024
Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, a new study by researchers at the Radcliffe Department of Medicine’s Diabetes Trial Unit has found.
Early blood glucose control for people with type 2 diabetes is crucial for reducing complications and prolonging life
18 May 2024
Research led by scientists from the Universities of Oxford and Edinburgh has found that early good blood glucose control can minimise the lifetime risk of diabetes-related complications, including heart attacks, kidney failure and vision loss.
The LEGEND-D Trial – which aims to prevent low blood sugar levels in type 1 diabetes – is open to recruitment
16 April 2024
The first participant has completed initial study activities and is now randomised to one of the trial’s arms.
Latest publications
-
Enhancing postpartum cardiometabolic health for women with previous gestational diabetes: Next steps and unanswered questions for pharmacological and lifestyle strategies
Journal article
Golubic R. et al, (2024), Diabetes, Obesity and Metabolism
-
Abstract 4144972: Predictors of cardiovascular disease risk and total mortality: Findings from the UK Biobank.
Journal article
Agwara EO. et al, (2024), Circulation, 150
-
Predictors of cardiovascular disease risk: findings from the National Survey of Health and Development Cohort
Journal article
Agwara E. et al, (2024), European Heart Journal, 45
-
Younger-onset compared with later-onset type 2 diabetes: an analysis of the UK Prospective Diabetes Study (UKPDS) with up to 30 years of follow-up (UKPDS 92).
Journal article
Lin B. et al, (2024), Lancet Diabetes Endocrinol
-
Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial.
Journal article
Neves JS. et al, (2024), Eur J Heart Fail